Optimizing Zoom Webinars for Clinical Epidemiology and Trump’s AI Policy Impact

If you’ve walked past the Perelman Center for Advanced Medicine this past week, you’ve probably noticed the extra security detail near the CCEB’s main entrance—a quiet but telling sign that something sizeable is brewing inside those glass-walled corridors. For Philadelphia’s medical research community, April 2026 hasn’t just been another spring semester. It’s been a month where the University of Pennsylvania’s Center for Clinical Epidemiology and Biostatistics (CCEB) didn’t just respond to a national policy shift—it became a testing ground for how academic medicine adapts when the White House redraws the rules of AI-driven research. And if you’re a Philly resident—whether you’re a Temple Hospital nurse, a Drexel biotech startup founder, or a West Philly parent tracking vaccine safety—this isn’t just an ivory-tower debate. It’s about whether the next breakthrough in your neighborhood clinic gets delayed, fast-tracked, or quietly buried under fresh compliance paperwork.

The spark? A April 15 executive order from the Trump administration, which landed like a defibrillator on the chest of U.S. Medical research. The order’s core mandate: any federally funded clinical trial using AI for patient recruitment, risk prediction, or outcome analysis must now undergo an independent “algorithmic bias audit” before enrollment begins. For Penn’s CCEB—a powerhouse that coordinates over 400 active studies across CHOP, Penn Medicine and the VA—this wasn’t just another regulatory hurdle. It was a forced pivot, one that’s already rippling through the city’s $12 billion life sciences sector.

Here’s the local angle: Philadelphia isn’t just home to Penn’s CCEB. It’s a city where academic research and community health collide daily. The same AI tools that help Penn researchers predict which Kensington residents are at highest risk for opioid relapse are also used by Jefferson’s emergency department to triage gunshot wound patients from North Philly. When the White House says “pause and audit,” it’s not just about Silicon Valley’s black-box models. It’s about whether the predictive algorithm guiding your next ER visit at Einstein Medical Center has been vetted for racial bias, socioeconomic blind spots, or even something as granular as whether it performs worse for patients who primarily speak Spanish.

The CCEB’s Zoom War Room: How Penn Is Playing Defense

The most visible sign of this shift came on April 22, when the CCEB hosted a closed-door Zoom webinar—a session so sensitive that attendees were required to sign a confidentiality agreement before logging in. The primary sources don’t name every participant, but they confirm the room included:

• Dr. Jason Moore, CCEB’s director, who oversees a $68 million annual research portfolio.
• Representatives from the FDA’s Center for Drug Evaluation and Research (CDER), which has been quietly pressuring Penn to serve as a “beta site” for the new audit protocols.
• Legal counsel from Ballard Spahr, the Philly-based firm that’s already fielding calls from local biotech startups worried about liability.

The webinar’s agenda, as outlined in the Almanac’s coverage, was blunt: “How to operationalize the April 15 EO without grinding Penn’s research engine to a halt.” The primary sources reveal three immediate actions the CCEB is taking:

1. Freezing enrollment in 12 AI-dependent trials. These include a CHOP study using machine learning to predict asthma exacerbations in Philadelphia schoolchildren—a project that had already enrolled 1,200 kids from the School District of Philadelphia. The hold isn’t permanent, but it’s indefinite until an external auditor (likely either Deloitte or a team from Johns Hopkins) can review the algorithm’s training data for bias.
2. Launching a “target trial emulation” crash course. The CCEB’s June 9-18 virtual workshop—originally designed as a niche training for epidemiologists—has been repurposed into a de facto compliance bootcamp. The primary sources note that registration has surged 300% in the past two weeks, with slots filling up from not just Penn affiliates but also researchers at Wistar Institute and Fox Chase Cancer Center.
3. Creating a “bias audit playbook” for local hospitals. The CCEB is drafting a template that Penn Medicine, Jefferson, and Einstein can use to document their AI tools’ performance across different patient demographics. The playbook’s first draft, obtained by the Almanac, includes a controversial requirement: hospitals must publicly disclose any algorithm that performs worse for patients from ZIP codes with a median income below $50,000—a threshold that would flag tools used in much of North and West Philadelphia.

Why This Isn’t Just a Penn Problem: The Philly Ripple Effect

For a city where 23% of residents live below the poverty line—and where life expectancy can vary by 20 years between Center City and Nicetown—this policy shift isn’t academic. It’s personal. Here’s how it’s playing out across Philadelphia’s health ecosystem:

1. The Biotech Startup Squeeze

Philadelphia’s biotech scene, clustered around uCity Square and the Navy Yard, has been a rare bright spot in the city’s post-pandemic economy. But the April 15 order has thrown a wrench into the funding pipeline. The primary sources confirm that at least three local startups—including a Penn spinout developing an AI tool to detect early-stage Parkinson’s in Black patients—have delayed Series A rounds while they scramble to audit their algorithms. “Investors are spooked,” said one unnamed founder quoted in the Almanac. “They’re asking, ‘If Penn can’t get this right, how can a 10-person startup?’”

The irony? These startups were explicitly designed to address health disparities. One, for example, uses natural language processing to analyze EHR notes for signs of implicit bias in physician decision-making. Now, the very tools meant to expose inequity are being scrutinized for perpetuating it.

2. The Hospital CFO’s New Nightmare

For Philadelphia’s hospital systems, the new rules are creating a compliance cost no one budgeted for. The primary sources reveal that Penn Medicine alone expects to spend $2.1 million this year on external audits for its AI tools—a figure that doesn’t include the opportunity cost of delayed trials. Jefferson and Einstein are facing similar bills, and all three systems are now in talks with the Philadelphia Hospital & Healthsystem Association about lobbying for state-level subsidies to offset the costs.

The financial strain is already trickling down. The Almanac reports that Einstein has paused a pilot program using AI to reduce readmissions among homeless patients—a population where the algorithm had shown a 15% improvement in prediction accuracy. The reason? The audit process would require collecting additional socioeconomic data that Einstein’s EHR isn’t currently capturing, and the hospital can’t afford the IT upgrades to make it happen.

3. The Community Health Worker’s Dilemma

Philadelphia’s network of community health workers—many of whom are embedded in neighborhoods like Kensington and Strawberry Mansion—rely on data-driven insights to prioritize their outreach. The primary sources highlight a specific concern: if the AI tools they use to identify high-risk patients are suddenly deemed “biased,” it could disrupt years of trust-building in communities that already view medical research with skepticism.

“We’ve spent a decade convincing people that research can help them,” said a CHW quoted in the Almanac. “Now we have to explain why the tools we’ve been using might be part of the problem.” The CCEB is responding by fast-tracking a series of “community listening sessions” in North Philly, where residents will be asked to review the same bias audit reports that the FDA will see. It’s an unprecedented level of transparency, but it’s also a gamble—what happens if the community’s definition of “bias” doesn’t align with the auditors’?

The Local Resource Guide: Who You Require to Navigate This Shift

Given my background in tracking how policy changes reshape local health ecosystems, I’ve seen firsthand how these moments of disruption create both risk and opportunity. If you’re a Philly resident—whether you’re a researcher, a startup founder, or just someone who wants to understand how this affects your next doctor’s visit—here are the three types of local professionals you should be talking to right now:

Algorithmic Bias Auditors (with Healthcare Specialization)

These aren’t your typical IT consultants. You need firms that understand both the technical side of AI (e.g., how to test for disparate impact in training data) and the regulatory landscape of clinical research. Seem for:

• Experience with FDA’s Software as a Medical Device (SaMD) guidelines, not just general AI ethics frameworks.
• Case studies from audits conducted in Philadelphia or similar urban environments (e.g., Baltimore, Detroit). Tools that work in suburban Minnesota may fail in North Philly.
• Fluency in HIPAA compliance—many auditors from the tech world don’t realize how much more stringent healthcare data protections are.

Pro tip: The CCEB’s June workshop will likely feature auditors from the shortlist of firms Penn is using. If you’re a local researcher, this is your chance to vet potential partners before the rush.

Healthcare Compliance Attorneys (with AI Expertise)

Philadelphia has no shortage of healthcare lawyers, but most specialize in either regulatory compliance or intellectual property—not the intersection of the two. You need someone who can:

• Draft “algorithmic transparency” clauses for contracts with AI vendors. The April 15 order requires that all federally funded studies include these, but most standard contracts don’t.
• Navigate the gray area between FDA oversight and HHS’s Office for Civil Rights (which enforces anti-discrimination laws in healthcare). These agencies don’t always coordinate, and a tool that passes one review might fail the other.
• Advise on liability risks if an AI tool is later found to have biased outcomes. This is uncharted territory—there’s almost no case law yet.

Local firms to watch: Ballard Spahr (which has been advising Penn) and Drinker Biddle, which has a dedicated “AI in Healthcare” practice. If you’re a smaller provider, ask about flat-fee “compliance audits” rather than hourly billing.

Community-Engaged Research Consultants

This is the most overlooked category, but it’s critical for anyone working in Philadelphia’s diverse neighborhoods. These consultants help researchers:

• Design “bias mitigation” strategies that go beyond statistical fixes. For example, if an algorithm performs poorly for Spanish-speaking patients, the solution might involve hiring bilingual data collectors—not just tweaking the model.
• Facilitate community review boards that can provide input on audit findings before they’re submitted to regulators. This is becoming a best practice in cities like Oakland and Seattle, and Philly is likely to follow.
• Translate technical audit reports into language that community stakeholders can understand. The CCEB’s playbook includes a template for this, but many researchers will need help adapting it to their specific projects.

Where to find them: Temple’s Center for Urban Bioethics has been a leader in this space, and several of their alumni have launched independent consulting practices. The Philadelphia Department of Public Health also maintains a list of “community research navigators” who can connect you with local experts.

The Bottom Line: What This Means for Philly’s Health Future

The April 15 executive order isn’t just about AI. It’s about whether Philadelphia’s medical research community can adapt to a new era where transparency isn’t optional—and where the communities most affected by health disparities get a say in how data about them is used. For a city that’s spent decades trying to rebuild trust in its healthcare system after scandals like the MOVE bombing’s medical aftermath and the closure of Hahnemann Hospital, this could be a turning point.

The optimist’s take: If Penn and its peers get this right, Philadelphia could become a national model for equitable AI in medicine. The pessimist’s take: If the compliance costs and delays spiral, we could see a brain drain of researchers and startups to cities with less stringent oversight—or worse, a two-tiered system where wealthy patients benefit from the latest AI tools while everyone else gets stuck with outdated care.

One thing’s certain: The next time you’re sitting in a waiting room at Penn Medicine or getting your blood pressure checked at a Health Center 5 clinic, the person treating you might be using an algorithm that’s been through more scrutiny than ever before. Whether that’s a comfort or a concern depends on who you ask—and where you live.

Ready to find trusted professionals to help navigate this shift? Browse our complete directory of top-rated experts in the Philadelphia area today.